Fabrazyme 35 MG vials
Ended Awarded
- Contract number
- SPE2DB25FY21G
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,867
Award facts
- Contract value 100% obligated
- $12,867.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,867.46 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for 35 mg vials of Fabrazyme, with an ultimate completion date of May 9, 2025. This delivery order was issued without set-aside designation and represents a single purchase from DMS Pharmaceutical Group's larger indefinite delivery contract with DLA. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, holds a significant $499,999,999 indefinite delivery contract with DLA under the SPE2DB program, which remains valid through November 2026 and enables the agency to procure a comprehensive range of pharmaceutical products for military healthcare facilities.
Fabrazyme, an enzyme replacement therapy used to treat Gaucher disease and Fabry disease, is a specialized pharmaceutical product typical of DMS Pharmaceutical Group's federal contract portfolio, which includes branded medications, biologics, and medical consumables supporting Department of Defense healthcare systems nationwide. As a registered federal contractor since 2001, DMS Pharmaceutical Group has consistently secured delivery orders across diverse therapeutic categories through its established relationship with DLA, positioning the company as a critical supplier within the federal pharmaceutical supply chain for military health facilities.
Quick answers
Who was awarded contract SPE2DB25FY21G?
SPE2DB25FY21G was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on April 18, 2025.
How much is contract SPE2DB25FY21G worth?
The government has obligated $12,867 on SPE2DB25FY21G.
Is contract SPE2DB25FY21G an order under another contract?
Yes. SPE2DB25FY21G is a delivery order under SPE2DB22D9362, an indefinite delivery contract.
Was contract SPE2DB25FY21G competed?
The extent of competition for SPE2DB25FY21G was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award